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GSK-3bProtocadherin 9 (PCDH9) was found frequently lost in hepatocellular carcinoma (HCC). Here we investi-
gated the role of PCDH9 in the development of HCC. We conﬁrmed that PCDH9 was down-regulated in
HCC tissues and cell lines compared with the adjacent non-tumor tissues. PCDH9 downregulation was
signiﬁcantly associated with malignant portal vein invasion of HCC patients. Gain- and loss-of-function
studies revealed that downregulation of PCDH9 facilitated tumor cell migration and epithelial–mesen-
chymal transition (EMT). We identiﬁed PCDH9 as a novel regulator of EMT by increasing the activity
of GSK-3b and inhibiting Snail1, indicating its potential therapeutic value for reducing metastasis of HCC.
 2014 The Authors. Published by Elsevier Inc. This is an open access article under the CC BY-NC-ND
license (http://creativecommons.org/licenses/by-nc-nd/3.0/).1. Introduction
Hepatocellular carcinoma (HCC) is the ﬁfth most common
malignancy and ranks third in global cancer mortality rates [1].
Despite the current use of hepatectomy and liver transplantation
to improve the radical cure rates, the long-term outcome for HCC
patients after effective treatment still remains generally poor [2].
The main reason for the high early recurrence of HCC is the high
potential for vascular invasion and metastasis [3,4]. However, the
mechanisms underlying HCC metastasis are still largely unknown.
It is thus necessary to discover biological markers that predict early
tumor metastasis and identify novel therapeutic targets.
The protocadherins (PCDHs) are a group of calcium-depen-
dent adhesion proteins which make up the largest subfamily(about 80 members) of the cadherin superfamily [5]. In contrast
to classical cadherin, which potentiates strong cell–cell adhesion
through homophilic interactions, the PCDHs appear to have
more varied physiological functions [6,7]. Thus, they act both
as a mediator of cell–cell adhesion and as a regulator of other
molecules [8]. Based on the genomic structure, the PCDHs
family can be divided into two groups, clustered PCDHs and
non-clustered PCDHs [9]. Human non-clustered PCDH genes
are often located at three chromosomal loci: 4q28–31, 5q31–
33 and 13q21 [6]. Recently, PCDHs around 13q21 (PCDH8,
PCDH9, PCDH10, PCDH17 and PCDH20) have been reported as
candidate tumor suppressor genes, suggested that these PCDHs
might be broadly involved in tumor suppression in a variety
of tumors [10–14].
The protocadherin 9 (PCDH9) gene has been mapped to
13q21.32 in humans and it encodes a protein which is expressed
in a broader variety of tissues [5]. Recent studies have shown that
PCDH9 expression was down regulated in non-nodal mantle cell
lymphoma (MCL) and glioblastoma, as a result of gene copy num-
ber alterations, and that exogenous expression of PCDH9 could
inhibits glioma cell invasion [11,15]. Although these results sug-
gest that down-regulation of PCDH9may be a factor in the carcino-
genesis of MCL and glioblastoma, the association between PCDH9
and the pathogenesis of many other cancers remains elusive and
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molecular levels.
We have previously performed a 2-Mb array based CGH analy-
sis and identiﬁed deletions of PCDH9 gene in 24% (6/25) of HCC
tumor specimens tested [16]. This frequent deletion of PCDH9 in
HCC has prompted us to explore whether it might act as a potential
tumor suppressor gene in HCC. In the present study, we validated
the down-regulation of PCDH9 in HCC tumor tissues. We found
that PCDH9 could inhibit EMT and cell migration of HCC cells
through activating GSK-3b signaling and inhibiting the expression
of transcription factor Snail1. Our ﬁndings indicated that PCDH9
had a potential function to play a tumor-suppressor role in HCC
and re-expression of PCDH9 might serve as a potential therapeutic
strategy for HCC.2. Materials and methods
2.1. Liver cancer cell lines and HCC tissues
Human liver cancer cell lines (SNU-449, SNU-182, Huh-7, SNU-
387, SK-HEP-1, SMMC-7721, PLC/PRF/5 and Hep3B) were pur-
chased from ATCC. All cells were maintained in RPMI 1640 or Dul-
becco’s modiﬁed Eagle’s medium (DMEM) (Gibco, Carlsbad, CA,
USA) supplemented with 10% fetal bovine serum (FBS) (Gibco,
Carlsbad, CA, USA).
A total of 120 HCC patients who underwent surgery at the
Henan Oncology Hospital (Zhengzhou, Henan, China) from 2009
to 2013 were enrolled in this study. The clinico-pathological char-
acteristics of the patients are listed in Supplementary Table S1. Dis-
ease-free liver tissues (n = 12) were obtained from liver donors in
the same hospital. This study was approved by the Ethics Commit-
tee of Peking University Health Science Center.2.2. Quantitative reverse transcription-PCR (qRT-PCR)
Quantitative real-time RT-PCR was performed on a LightCycler
480II Realtime PCR Detection System (Roche, Indianapolis, IN,
USA). CTBP1 was included as a house keeping gene control to nor-
malize expression levels [17,18]. The primers used for qRT-PCR
assay are listed in Supplementary Table S2.2.3. Immunohistochemistry and Western blot assay
Immunohistochemical staining was performed using the 2-step
plus Poly-HRP Anti-rabbit lgG Detection System (ZSGB-Bio, Beijing,
China) according to the manufacturer’s recommendations. For
direct Western blot analysis was performed as reported previously
[19]. The antibodies used in this study were listed in Supplemen-
tary Table S3.2.4. Plasmid constructions
The full-length PCDH9 cDNA with a His-tag at its C-terminal
was cloned into the pIRES2-EGFP expression vector (BD Biosci-
ences Clontech, USA). The pAAV-U6 vector encodes two effective
shRNA (shRNA1 and shRNA2) against PCDH9. Oligonucleotides of
the two shRNAs were showed in Supplementary Table S2.2.5. Trans-well migration assay and Wound-healing assay
The trans-well migration assay and wound-healing assay was
performed as reported previously [19].2.6. Statistical analysis
All statistical analyses were performed with SAS 9.1 software
(SAS Institute Inc., Cary, NC, USA). The Student’s t test was used
to determine differences between two groups. The comparison of
patient’s PCDH9 expression was analyzed using the chi-square test,
when n < 5 Fisher’s exact test was used. All tests were 2-sided sta-
tistical analyses and a p-value of less than 0.05 was taken as indic-
ative of statistically signiﬁcant difference.3. Results
3.1. Down-regulation of PCDH9 expression in HCC tissues
We ﬁrst detected the PCDH9 mRNA level in 8 HCC derived cell
lines, 5 of them (Huh-7, SMMC-7721, SK-HEP-1, SNU-182 and
SNU-449) showed down-regulation of PCDH9 as compared to the
level in normal liver tissues (Fig. 1A). Then the PCDH9 mRNA levels
were compared between paired human HCC samples, compared to
that in the corresponding adjacent non-tumor tissue, PCDH9
mRNA was down-regulated in a majority of tumor derived samples
(61%, 73/120, p = 0.0082) (Fig. 1B). The down regulation of PCDH9
expression was further conﬁrmed at the protein level, by both
Western blot analysis (Fig. 1C) and immunohistochemistry
(Fig. 1D).
3.2. PCDH9 down-regulation is associated with malignant portal vein
invasion in HCC
We further analyzed the correlation between PCDH9 expression
and the clinico-pathological characteristics of HCC patients. Strati-
ﬁed statistical analysis revealed that low expression of PCDH9 was
signiﬁcantly correlated with malignant portal vein invasion (34.2%
vs. 65.8%, p = 0.0354) (Table 1). No association was found between
PCDH9 expression and gender, age, cirrhosis background, tumor
size or AFP level. Interestingly, the Mantel-Cox test also showed
that patients with PCDH9 down-regulation in tumors tissue was
more likely had a poor total survival of post curative resection,
however such correlation did not reach statistical signiﬁcance
(p = 0.2532) (Supplementary Fig. S1).
3.3. PCDH9 suppresses migration of HCC cells
To further explore the role of PCDH9 in HCC, the HCC derived
cell line SNU-449 which showed extremely low levels of endoge-
nous PCDH9 expression was transfected with either a PCDH9
expression construct or control pIRES2-EGFP plasmid. Additionally,
two HCC cell lines (Hep3B and PLC/PRF/5) that exhibited high lev-
els of endogenous PCDH9 expression were transfected with either
PCDH9 knockdown plasmid (shRNA1 and shRNA2) or control
pAAV-U6 plasmid. Following G418 selection, SNU-449 cells stably
expressing ectopic PCDH9, as well as the Hep3B and PLC/PRF/5
cells in which endogenous PCDH9 expression suppressed were
obtained. The alterations of PCDH9 expression in these experimen-
tal cell lines were conﬁrmed by real-time RT-PCR andWestern blot
assays (Fig. 2A).
In order to investigate the effects of PCDH9 expression on HCC
cell motility and migration, trans-well assay and wound-healing
assay were conducted. By using Trans-well assay, we found that
the number of SNU-449 cells migrating through membrane parti-
tion into the lower chamber was signiﬁcantly lower in SNU-449
cells ectopically expressing PCDH9 than in the control cells
(p = 0.0007, Fig. 3B). By contrast, in both Hep3B and PLC/PRF/5
clones in which PCDH9 expression had been knocked down, the
number of cells migrating through the partitioning membrane
Fig. 1. Down regulation of PCDH9 in HCC cell lines and tumor tissues. (A) Expression of PCDH9 in 8 HCC cell lines and 12 control normal liver tissues (mean ± sd; n = 3). (B)
Expression of PCDH9 in 120 pairs of HCC and adjacent non-tumor tissues. The lines in the grouped column scatter indicate mean values for tumor and adjacent non-tumor
tissues. (C) Expression of PCDH9 in 6 pairs of HCC and adjacent non-tumor tissues as detected by Western blot assay. a-Tubulin was used as a loading control. (D)
Representative immunohistochemistry results showing the difference in expression of PCDH9 between HCC tumor tissues (T) and adjacent non-tumor tissues (NT).
Table 1
Association of PCDH9 downregulation with clinical pathology parameters in HCC.
Characteristics T < N (n = 73) TP N (n = 47) p value
Gender 0.6483
Male 46 27
Female 27 20
Age 0.1486
<50 33 15
P50 40 32
Portal vein invasion 0.0354
Present 25 7
Absent 48 39
N/A 0 1
Tumor size 0.6411
P5 cm 53 35
<5 cm 17 12
N/A 3 0
Tumor encapsulation 0.4252
Complete 56 41
Incomplete 13 6
N/A 4 0
Intrahepatic dissemination 0.6894
Present 25 15
Absent 47 32
N/A 1 0
AFP level 0.3601
P400 35 17
<400 36 30
N/A 2 0
Liver cirrhosis 0.2484
I–III 47 35
IV–VI 26 12
T: tumor tissues; N: non-tumor tissues; N/A: not available.
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(Fig. 2B). In consistence with above observation, When a scratch
was created in the monolayer cells, restoration of PCDH9 levels
by ectopic expression caused SNU-449 to require a longer time
to re-ﬁll the gap compared to that seen for control clones
(p = 0.0313, Fig. 2C). By contrast, the knock-down of PCDH9
expression in Hep3B clones, promote cell migration at 24 h and
36 h post scratching compared with the appropriate controls
(p = 0.0221 and p = 0.0401, Fig. 2C). Similar results were obtained
from PLC/PRF/5 clones (p = 0.0246 and p = 0.0251, Fig. 2C).3.4. PCDH9 expression inhibits EMT in HCC derived cells
During cell culture of SNU-449 cells ectopically expressing
PCDH9, we noticed a loss of mesenchymal morphologic feature
and re-emergence of epithelial features (Fig. 3A). These morpho-
logical changes prompted us to test the expression of a series of
key EMT markers. Quantitative RT-PCR assays revealed that levels
of a number of mesenchymal markers including N-cadherin
(CDH2), Vimentin (VIM) and Fibronectin (FN) were signiﬁcantly
decreased. By contrast, the expression of epithelial markers, such
as E-cadherin (CDH1, 13.5-fold up), Occludin (OCLN, 6.5-fold up),
Desmoplakin (DSP, 3.7-fold up) and Keratin 18 (KRT18, 2.2-fold
up) were all markedly increased (Fig. 3B). It is also noteworthy that
knocking down PCDH9 expression in Hep3B or PLC/PRF/5 cells
resulted in increased expression of mesenchymal markers and sup-
pression of epithelial marker (Fig. 3C). The altered expression of
the mesenchymal and epithelial markers E-cadherin, Snail1 and
N-cadherin were independently conﬁrmed using Western blot
analysis (Fig. 3D).
Fig. 2. PCDH9 expression can suppress cell migration in HCC derived cell lines. (A) The expression of PCDH9 in stable cell clones overexpressing and having had expression
knocked down was measured by quantitative RT-PCR (mean ± sd; n = 3) and Western blot analysis, respectively. (B) Shows cell motility as determined in a wound-healing
assay. All experiments were performed in triplicate, with the scratch area being arbitrarily assigned a value of 1.0 at time 0. (C) Shows are presentative trans-well migration
assay and histograms of the number of cells migrating through the partitioning membrane. The columns show the mean for three separate experiments, each of which was
done in triplicate; bars, SD. ⁄p < 0.05, ⁄⁄p < 0.005 versus appropriate controls (Student’s t test).
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Snail1 plays a key role in the complex signaling network orches-
trated during epithelial to mesenchymal transitions, and it is rapid
turnover dependent on the GSK-3bmediated phosphorylation on it
[20,21]. To determine whether GSK-3b was involved in the Snail1
down regulation induced by ectopic PCDH9, the level of phos-
pho-GSK-3b (Ser9), the inactive form of GSK-3b, was measured
by western blot assay. As shown in Fig. 4A, the level of phospho-
GSK-3b (Ser9) was decreased in SNU-449 cells ectopically express-
ing PCDH9, whereas knockdown of PCDH9 expression in Hep3B
and PLC/PRF/5 cells resulted in its level being increased. These
results suggest that PCDH9 expression can modulate GSK-3b
kinase activity.
To verify whether the activation of GSK-3b is required for
PCDH9 to inhibit EMT, SNU-449 cells were treated with the GSK-
3b inhibitor lithium chloride (LiCl) and the expression of EMT
markers were analyzed. As showed in Fig. 4B, western blot assay
revealed that treatment of SNU-449 cells with LiCl could reversePCDH9 mediated Snail1 down-regulation. LiCl treatment also
increased N-cadherin and decreased E-cadherin levels. Meanwhile,
LiCl treatment eliminated the PCDH9-induced expression change
of other EMT markers (Fig. 4C).
Both Akt and Erks can phosphorylate GSK-3b at the crucial Ser9
residue. Therefore, western blot analysis was carried out and the
results demonstrated the down-regulation of phospho-Akt
(Ser473) and phospho-Erk (Thr202/Tyr204) in SNU-449 cells
ectopically expressing PCDH9. By contrast, knockdown of endoge-
nous PCDH9 expression resulted in the up-regulation of phospho-
Akt and Erk in Hep3B and PLC/PRF/5 cells (Fig. 4A), suggesting
strongly that PCDH9 might activate the GSK-3b via modulating
Erks and Akt activation.4. Discussion
HCC development is clearly a multistep process involving both
the activation of oncogenes and the silencing of tumor suppressor
Fig. 3. Regulation of PCDH9 expression on EMT in HCC derived cell lines. (A) Shows morphological changes in SNU-449 cells ectopically expressing PCDH9. (B) Shows
quantitative real time RT-PCR analysis of indicated EMT biomarkers in SNU-449 cells ectopically expressing PCDH9. The log2ratios of EMT markers, which reﬂect the change
of expression levels, were mufﬂed to less than 1 or 1. The PCDH9/vector ratio shown is a log2ratio scale where 0 means equal, +1 means double and 1 means 50%
(mean ± sd; n = 3). (C) Shows quantitative real time RT-PCR analysis of indicated EMT biomarkers in Hep3B or PLC/PRF/5 cells in which PCDH9 expression has been
suppressed. The log2ratio of shRNA1/mock or shRNA2/mock ratio is calculated. (D) Shows Western blot analysis of the EMT-related molecules E-cadherin, N-cadherin and
Snail1.
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region 13q is one of the most frequently affected chromosome
arms in a number of cancers including HCC [22,23]. A recently pub-
lished study has reported that allelic losses on 13q can result in
more aggressive tumor behavior, suggesting that this chromo-
somal region is likely to contain TSGs [24,25]. In this study, we pro-
vide direct evidence for the tumor-suppressing role of PCDH9,
which is located on chromosome 13q21.32 and frequently deleted
in HCC.
PCDH8, PCDH10, PCDH17 and PCDH20 are co-localized with
PCDH9 on chromosome 13q21 [6]. The genetic and/or the epige-
netic aberration of these PCDHs have been found in many kinds
of tumors [4,6,10,12,14]. However, the expression and molecularfunction of PCDH9 in HCC has not previously been analyzed in
any detail. In this study, we detected the PCDH9 mRNA level in
120-paired human HCC tissues and 8 HCC derived cell lines. The
results showed that expression of PCDH20 is frequently decreased
in HCC tumor tissues (73 of 120, 61%) and cell lines (5 of 8, 62.5%).
Further analysis revealed that reduced expression of PCDH9 was
signiﬁcantly associated with the malignant portal vein invasion
of HCC patients, suggested that down-regulation of PCDH9 plays
a critical role in establishment of HCC metastasis. In consistent
with the above-suggested function, overexpression of PCDH9 in
HCC derived cell lines inhibited cell migration, whereas loss of
PCDH9 expression enabled HCC cells to gain higher invasive capa-
bility. These results further conﬁrmed the migration-suppressive
Fig. 4. Activation of GSK-3b is required for PCDH9-induced modulation of EMT. (A) Shows Western blot of phosphorylated GSK-3b, Erks, and Akt in SNU-449 cells ectopically
expressing PCDH9 or Hep3B or PLC/PRF/5 cells in which PCDH9 expression has been suppressed. (B and C) Shows the expression of EMT molecular biomarkers determined in
SNU-449 cells after LiCl treatment by Western blot analysis (B) and real-time RT-PCR (C). (D) The Intracellular signaling cascades of EMT inhibition triggered by PCDH9. ‘?’
means positive regulation, ‘–|’ means negative regulation, an un-broken line means direct regulation and a dotted line means indirect regulation.
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expression of PCDH9 mRNA expression in primary HCC tissues
(61%) was higher than that expected from the gene loss (24%), sug-
gesting that other mechanisms such as epigenetic regulation and
post-translational modiﬁcation, which also contribute to the
down-regulation of PCDH9 in HCC.
EMT is a key event in the tumor invasion and metastasis process
by epithelial cell layers lose polarity and cell–cell contacts and
remodel the cytoskeleton [26,27]. The decreased invasive capabil-
ity and morphological changes of SUN-449 cell line induced upon
ectopic PCDH9 expression prompted the investigation of PCDH9’sinvolvement in the regulation of the epithelial–mesenchymal
transition in this study. As expected, ectopic expression of PCDH9
could up-regulate epithelial markers, such as E-cadherin, Occludin
and KRT18, and down-regulate mesenchymal markers such as N-
cadherin, Vimentin and Fibronectin, and particularly the EMT-
associated transcription regulator Snail1. Consistent with these
results, knockdown of PCDH9 expression caused a decrease in
the expression of these epithelial markers and an increase in
expression of mesenchymal markers. The expression pattern of
these EMT markers are consistent with the alteration of migratory
properties induced by PCDH9 in HCC cells, supporting that PCDH9
P. Zhu et al. / Biochemical and Biophysical Research Communications 452 (2014) 567–574 573may be a key regulator of invasion and metastasis by inhibiting
EMT of HCC cells. This involvement of PCDH9 in regulating EMT
also provided an explanation for the association of the down-regu-
lation of PCDH9 expression with the presence of portal vein inva-
sion in HCC patients.
Amongst the various biomarkers of EMT, Snail1 is generally
considered to be a critical transcriptional regulator because of its
direct suppressive effect on CDH1 (encoding E-cadherin) promoter
[20,28]. In addition, GSK-3b has been recognized as the primary
kinase involved in regulating both the sub-cellular location and
stability of the Snail1 protein [21]. It was therefore plausible to
hypothesize that PCDH9 may down-regulate Snail1 expression
through activating the GSK-3b kinase. As expected, our data dem-
onstrated that PCDH9 could activate the GSK-3b kinase and reduce
the expression of Snail1. Treatment of cells with LiCl, a known
inhibitor of GSK-3b abolished down-regulation Snail1 induced by
ectopically expressing of PCDH9, meanwhile the changes of EMT
biomarkers disappeared. These results allow the construction of a
putative pathway for PCDH9 conducting its biological action
(Fig. 4D). This proposes that, acting through an undeﬁned mecha-
nism, PCDH9 inhibits both Akt and Erks kinase activities and this
leads to the activation of the GSK-3b kinase, which in turn suppress
the Snail1 expression. Reduced expression of Snail1 emancipates
the transcription of E-cadherin and results in an up-regulation of
its expression, which inhibits the EMT process and cell migration
of HCC cells.
Several recent studies have indicated that PCDH19, a member of
PCDHs subfamily might act synergistically with N-cadherin to reg-
ulate cell adhesion during anterior neurulation in zebraﬁsh [29,30].
However, PCDH9 showed neither homophilic interaction with
itself nor heterophilic adhesion with N-cadherin in the present
study (Supplementary Fig. S2), this is consistent with another
PCDH member PCDH20 which we recently demonstrated it as a
tumor suppression gene in HCC [19]. We found that both PCDH20
and PCDH9 could conduct their anti-tumor property through sup-
pressing activation of Akt and Erks and promoting GSK-3b kinase
activities [19]. Unlike PCDH20’s capability to inhibit Wnt/b-catenin
signaling via down-regulating b-catenin, PCDH9 could not sup-
press Wnt/b-catenin signaling pathway in HEK 293T or any of 5
HCC derived cell lines tested (Huh-7, SMMC-7721, SK-HEP-1,
SNU-182 and SNU-449) (data not shown). Instead, PCDH9 exhibits
its tumor suppressing function by down-regulating Snail1 and
inhibiting epithelial to mesenchymal transition. Though Snail1
and b-catenin are both downstream molecular of GSK-3b, the dif-
ferent modulation on GSK-3b signaling by PCDH9 and PCDH20
suggested that different members of PCDH could play diverse roles
as intracellular signaling regulators. Further study will be con-
ducted to determine the precise intracellular signaling and explore
other potential mechanisms of PCDH9 in the carcinogenesis of
HCC.
In summary, this study has shown for the ﬁrst time that PCDH9
acts as a potential tumor suppressor gene in HCC, and the loss of
PCDH9 expression appears to be a driver in a signiﬁcant fraction
of hepatocarcinogenesis.Grant support
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